BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang M, Hunter T, Slomovitz B, Schlumbrecht M. Impact of molecular testing in clinical practice in gynecologic cancers. Cancer Med 2019;8:2013-9. [PMID: 30848097 DOI: 10.1002/cam4.2064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wolford JE, Ferrigni E, Margul D, Herzog TJ. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01163-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Maruthi VK, Khazaeli M, Jeyachandran D, Desouki MM. The Clinical Utility and Impact of Next Generation Sequencing in Gynecologic Cancers. Cancers (Basel) 2022;14:1352. [PMID: 35267660 DOI: 10.3390/cancers14051352] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hinchcliff EM, Westin SN. Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls. Gynecol Oncol 2021;163:217-9. [PMID: 34756289 DOI: 10.1016/j.ygyno.2021.10.005] [Reference Citation Analysis]
4 Koskas M, Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 2021;155 Suppl 1:45-60. [PMID: 34669196 DOI: 10.1002/ijgo.13866] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
5 Somasegar S, Hoppenot C, Kuchta K, Sereika A, Khandekar J, Rodriguez G, Moore E, Hurteau J, Vogel TJ. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. Gynecol Oncol 2021;163:220-8. [PMID: 34511240 DOI: 10.1016/j.ygyno.2021.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Di Fiore R, Suleiman S, Ellul B, O'Toole SA, Savona-Ventura C, Felix A, Napolioni V, Conlon NT, Kahramanoglu I, Azzopardi MJ, Dalmas M, Calleja N, Brincat MR, Muscat-Baron Y, Sabol M, Dimitrievska V, Yordanov A, Vasileva-Slaveva M, von Brockdorff K, Micallef RA, Kubelac P, Achimaș-Cadariu P, Vlad C, Tzortzatou O, Poka R, Giordano A, Felice A, Reed N, Herrington CS, Faraggi D, Calleja-Agius J. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions. Cancers (Basel) 2021;13:493. [PMID: 33514073 DOI: 10.3390/cancers13030493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Watson CH, Broadwater G, Wong J, Spinosa D, de Oca MKM, Datto M, Green M, Hubbard C, McKinney M, McCall SJ, Havrilesky LJ, Strickler JH, Berchuck A, Strickland KC, Previs RA. Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. Target Oncol 2021;16:109-18. [PMID: 33400095 DOI: 10.1007/s11523-020-00785-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lai TS, Manrriquez E, Neal A, Memarzadeh S. Matched sequential tumor molecular profiling in solid malignancies may impact clinical practice. Cancer Genet 2021;252-253:73-9. [PMID: 33434795 DOI: 10.1016/j.cancergen.2020.12.008] [Reference Citation Analysis]
9 Pandita P, Wang X, Jones DE, Collins K, Hawkins SM. Unique Molecular Features in High-Risk Histology Endometrial Cancers. Cancers (Basel) 2019;11:E1665. [PMID: 31717878 DOI: 10.3390/cancers11111665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huang M, Hunter T, Slomovitz B, Schlumbrecht M. Impact of molecular testing in clinical practice in gynecologic cancers. Cancer Med 2019;8:2013-9. [PMID: 30848097 DOI: 10.1002/cam4.2064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]